{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:11:25Z","timestamp":1776852685260,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":987,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.anpedi.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,11,21]],"date-time":"2015-11-21T01:43:41Z","timestamp":1448070221000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aspectos inmunol\u00f3gicos de la leucemia mielobl\u00e1stica aguda"],"prefix":"10.1016","volume":"84","author":[{"given":"B.","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.M.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"San Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garc\u00eda-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Valent\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2015.07.004_bib0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/era.12.1","article-title":"Pediatric acute myeloid leukemia","volume":"12","author":"Kaspers","year":"2012","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40272-014-0067-3","article-title":"Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia","volume":"16","author":"Faulk","year":"2014","journal-title":"Paediatr Drugs."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"21","author":"Vyas","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/17474086.2014.878644","article-title":"Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: An open challenge","volume":"7","author":"Lucchini","year":"2014","journal-title":"Expert Rev Hematol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: An update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0205","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/CCO.0000000000000136","article-title":"Advances in treatment of de-novo pediatric acute myeloid leukemia","volume":"26","author":"Ribeiro","year":"2014","journal-title":"Curr Opin Oncol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0210","doi-asserted-by":"crossref","unstructured":"Gruber A, Downing G and Downing JR. Molecular genetic of acute myeloid lekemia in childhood leukemias. 3rd ed. Ching-Hon Pui, Memphis: Cambridge Medicine; 2012.","DOI":"10.1017\/CBO9780511977633.009"},{"key":"10.1016\/j.anpedi.2015.07.004_bib0215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bjh.13107","article-title":"Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy","volume":"168","author":"Karol","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fonc.2014.00055","article-title":"Molecular therapeutic approaches for pediatric acute myeloid leukemia","volume":"4","author":"Tasian","year":"2014","journal-title":"Front Oncol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0225","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0235","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.imlet.2013.09.013","article-title":"Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors","volume":"155","author":"Tettamanti","year":"2013","journal-title":"Immunol Lett."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2013.09.027","article-title":"Negative depletion of \u03b1\/\u03b2+ T cells and of CD19+ B lymphocytes: A novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation","volume":"155","author":"Locatelli","year":"2013","journal-title":"Immunol Lett."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0245","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","article-title":"The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells","volume":"14","author":"Rettinger","year":"2012","journal-title":"Cytotherapy."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0250","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/sj.leu.2401581","article-title":"Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children","volume":"13","author":"Bader","year":"1999","journal-title":"Leukemia."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0255","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1002\/cncr.28334","article-title":"Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia","volume":"119","author":"O\u2019Hear","year":"2013","journal-title":"Cancer."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0260","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0265","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/14653240601078721","article-title":"Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation","volume":"8","author":"Ruggeri","year":"2006","journal-title":"Cytotherapy."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0270","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0275","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0280","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000365632","article-title":"Human natural killer cells: Origin, receptors, function, and clinical applications","volume":"164","author":"Moretta","year":"2014","journal-title":"Int Arch Allergy Immunol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0285","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.smim.2014.02.004","article-title":"Natural killer cells in the treatment of high-risk acute leukaemia","volume":"26","author":"Locatelli","year":"2014","journal-title":"Semin Immunol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0290","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0295","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0300","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: Results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0310","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am J Hematol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2014.04.006","article-title":"Understanding the molecular pathogenesis of acute promyelocytic leukemia","volume":"27","author":"Lo-Coco","year":"2014","journal-title":"Best Pract Res Clin Haematol."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0320","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/157488807779317035","article-title":"Stem cell transplantation in pediatric leukemia and myelodysplasia: State of the art and current challenges","volume":"2","author":"Bierings","year":"2007","journal-title":"Curr Stem Cell Res Ther."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0325","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40272-013-0048-y","article-title":"Relapsed and refractory pediatric acute myeloid leukemia: Current and emerging treatments","volume":"16","author":"Davila","year":"2014","journal-title":"Paediatr Drugs."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0330","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1182\/blood-2013-11-536219","article-title":"Chouaib S. c-Myc regulates expression of NKG2D ligands ULBP1\/2\/3 in AML and modulates their susceptibility to NK-mediated lysis","volume":"123","author":"Nanbakhsh","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0335","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.leukres.2007.02.020","article-title":"Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis","volume":"31","author":"Rohner","year":"2007","journal-title":"Leuk Res."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0340","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class i specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0345","first-page":"15","article-title":"NK cell transplantation as consolidation therapy in children with acute myeloid leukemia-results from a pilot study","volume":"1","author":"Leung","year":"2014","journal-title":"Macs & More."},{"key":"10.1016\/j.anpedi.2015.07.004_bib0350","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/08880018.2013.802106","article-title":"Highlights of the third International Conference on Immunotherapy in Pediatric Oncology","volume":"30","author":"Brehm","year":"2013","journal-title":"Pediatr Hematol Oncol."}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403315002830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403315002830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T22:50:32Z","timestamp":1692139832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403315002830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1695403315002830"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2015.07.004","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspectos inmunol\u00f3gicos de la leucemia mielobl\u00e1stica aguda","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2015.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}